1. Antagonizing microRNA-19a/b augments PTH anabolic action and restores bone mass in osteoporosis in mice
- Author
-
Hanna Taipaleenmäki, Hiroaki Saito, Saskia Schröder, Miki Maeda, Ramona Mettler, Matthias Ring, Ewa Rollmann, Andreas Gasser, Carl Haasper, Thorsten Gehrke, Alexander Weiss, Steffen K Grimm, and Eric Hesse
- Subjects
Repressor Proteins ,Homeodomain Proteins ,Mice ,MicroRNAs ,Osteoblasts ,Bone Density ,Molecular Medicine ,Humans ,Animals ,Osteoporosis ,Bone and Bones - Abstract
Postmenopausal bone loss often leads to osteoporosis and fragility fractures. Bone mass can be increased by the first 34 amino acids of human parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), or by a monoclonal antibody against sclerostin (Scl-Ab). Here, we show that PTH and Scl-Ab reduce the expression of microRNA-19a and microRNA-19b (miR-19a/b) in bone. In bones from patients with lower bone mass and from osteoporotic mice, miR-19a/b expression is elevated, suggesting an inhibitory function in bone remodeling. Indeed, antagonizing miR-19a/b in vivo increased bone mass without overt cytotoxic effects. We identified TG-interacting factor 1 (Tgif1) as the target of miR-19a/b in osteoblasts and essential for the increase in bone mass following miR-19a/b inhibition. Furthermore, antagonizing miR-19a/b augments the gain in bone mass by PTH and restores bone loss in mouse models of osteoporosis in a dual mode of action by supporting bone formation and decreasing receptor activator of NF-κB ligand (RANKL)-dependent bone resorption. Thus, this study identifies novel mechanisms regulating bone remodeling, which opens opportunities for new therapeutic concepts to treat bone fragility.
- Published
- 2022